Osteoclastogenesis regulatory factors (RANK, RANKL and OPG) in osteolytic jaw lesions
AbstractReceptor activator of nuclear factor κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) are members of the superfamily of ligands and receptors of tumor necrosis factor relationed with bone metabolism. Osteoclastogenesis is regulated by these three proteins. The aim of this review was to assess the immunohistochemical expression of these proteins in osteolytic jaws lesions. Studies were identified by searching MEDLINE/Pubmed. The results link higher imunoexpression for RANKL compared to OPG in chronic periodontitis and in aggressive odontogenic tumors, and in less aggressive odontogenic tumors a tendency for higher expression for OPG. Taken into account this, OPG could be a good candidate for the treatment of oral lesions can often be widely destructive.
Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factorkappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl) 2001;79:243-53.
Aeschlimann D, Evans BA. The vital osteoclast: how is it regulated? Cell Death Differ 2004;11 Suppl 1:S5-7.
Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
Vega D, Maalouf NM, Sakhaee K. Clinical Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007;92:4514-21.
Fukada SY, Silva TA, Garlet GP, Rosa AL, da Silva JS, Cunha FQ. Factors involved in the T helper type 1 and type 2 cell commitment and osteoclast regulation in inflammatory apical diseases. Oral Microbiol Immunol 2009;24:25-31.
Moraes M, Lucena HF, Azevedo PR, Queiroz LM, Costa AD. Comparative immunohistochemical expression of RANK, RANKL and OPG in radicular and dentigerous cysts. Arch Oral Biol 2011;56:1256-63.
Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
Hofbauer LC. Pathophysiology of RANK ligand (RANKL) and
osteoprotegerin (OPG). Ann Endocrinol (Paris) 2006;67:139-41.
Andrade FR, Sousa DP, Mendonca EF, Silva TA, Lara VS, Batista AC. Expression of bone resorption regulators (RANK, RANKL, and OPG) in odontogenic tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:548-55.
Menezes R, Bramante CM, da Silva Paiva KB, Letra A, Carneiro E,
Fernando Zambuzzi W et al. Receptor activator NFkappaB-ligand
and osteoprotegerin protein expression in human periapical cysts
and granulomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008;473:139-46.
Tyrovola JB, Spyropoulos MN, Makou M, Perrea D. Root resorption and the OPG/RANKL/RANK system: a mini review. J Oral Sci 2008;50:367-76.
Wittrant Y, Théoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004;1704:49-57.
Baud’huin M, Lamoureux F, Duplomb L, Redini F, Heymann D. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 2007;64:2334-50.
Katagiri T, Takahashi N. Regulatory mechanisms of osteoblast and
osteoclast differentiation. Oral Dis 2002;8:147-59.
da Silva TA, Batista AC, Mendonca EF, Leles CR, Fukada S, Cunha FQ. Comparative expression of RANK, RANKL, and OPG in keratocystic odontogenic tumors, ameloblastomas, and dentigerous cysts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:333-41.
Vernal R, Dezerega A, Dutzan N, Chaparro A, León R, Chandía S, Silva A, Gamonal J. RANKL in human periapical granuloma: possible involvement in periapical bone destruction. Oral Dis 2006;12:283-9.
Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Töz H, Atilla G, Hughes FJ, Belibasakis GN. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol 2007;34:370-6.
Crotti T, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M et al. Receptor activator NF B ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003;38:380-7.
Lu HK, Chen YL, Chang HC, Li CL, Kuo MY. Identification of the
osteoprotegerin/receptor activator of nuclear factor-kappa B ligand
system in gingival crevicular fluid and tissue of patients with chronic periodontitis. Periodontal Res 2006;41:354-60.
Dereka XE, Markopoulou CE, Fanourakis G, Tseleni-Balafouta S, Vrotsos IA. RANKL and OPG mRNA level after non-surgical periodontal treatment. Inflammation 2010;33:200-6.
Kumamoto H, Ooya K. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. J Oral Pathol Med 2004;33:46-52.
Nonaka CF, Cavalcante RB, Nogueira RL, de Souza LB, Pinto LP.
Immunohistochemical analysis of bone resorption regulators (RANKL and OPG), angiogenic index, and myofibroblasts in syndrome and nonsyndrome odontogenic keratocysts. Arch Oral Biol 2012;57:230-7.
Min JK, Kim YM, Kim YM, Kim EC, Gho YS, Kang IJ, Lee SY, Kong YY, Kwon YG. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 2003;278:39548-57.
Menezes R, Garlet TP, Letra A, Bramante CM, Campanelli AP, Figueira Rde C, Sogayar MC, Granjeiro JM, Garlet GP. Differential patterns of receptor activator of nuclear factor kappa B ligand/osteoprotegerin expression in human periapical granulomas: possible association with progressive or stable nature of the lesions. J Endod. 2008;34:932-8.
Itonaga I, Hussein I, Kudo O, Sabokbar A, Watt-Smith S, Ferguson
D, Athanasou NA. Cellular mechanisms of osteoclast formation and
lacunar resorption in giant cell granuloma of the jaw. J Oral Pathol Med 2003;32:224-31.
Tobón-Arroyave SI, Franco-González LM, Isaza-Guzmán DM, Floréz-Moreno GA, Bravo-Vásquez T, Castañeda-Peláez DA, Vieco-Durán B. Immunohistochemical expression of RANK, GRalpha and CTR in central giant cell granuloma of the jaws. Oral Oncol 2005;41:480-8.
Chuang FH, Hsue SS, Wu CW, Chen YK. Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma. J Oral Pathol Med 2009;38:753-8.
Shibahara T, Nomura T, Cui NH, Noma H. A study of osteoclast-related cytokines in mandibular invasion by squamous cell carcinoma. Int J Oral Maxillofac Surg 2005;34:789-93.
The submission of originals to Odonto Ciência implies the transfer by the authors of the right for publication. Authors retain copyright and grant the journal right of first publication. If the authors wish to include the same data into another publication, they must cite Odonto Ciência as the site of original publication.
CREATIVE COMMONS LICENSE
As this journal is open access, the articles are allowed free use in scientific and educational applications, with citation of the source.
According to the type of Creative Commons License (CC-BY 4.0) adopted by Odonto Ciência, the user must respect the requirements below.
You are free to:
Share — copy and redistribute the material in any medium or format.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
However, only under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests Odonto Ciência endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
For more details on the Creative Commons license, please follow the link in the footer of this website.